About this Research Topic
October is the Liver Cancer Awareness Month and at Frontiers in Oncology we want to highlight the recent discoveries in the field and raise awareness of the importance of early diagnosis, multidisciplinary management, and technological innovation support.
Primary liver cancer represents a significant global health challenge, with its incidence steadily rising and posing substantial morbidity and mortality rates. This research topic in Frontiers in Oncology focuses on the latest advancements in the investigation and treatment of primary liver cancer, addressing hepatocellular carcinoma (HCC) and cholangiocarcinoma to provide insights into cutting-edge approaches to shaping the field and improving patient outcomes.
Contributing researchers delve into multifaceted aspects of primary liver cancer, including molecular pathogenesis, early detection methods, novel imaging techniques, personalized treatment strategies, and innovative therapeutic interventions. With an emphasis on translational research, this Research Topic aims to showcase studies that bridge the gap between laboratory discoveries and clinical applications. Investigations into the intricate molecular mechanisms underlying liver carcinogenesis offer new avenues for targeted therapies and biomarker development, while advancements in non-invasive imaging modalities enhance early diagnosis and disease staging.
The topic also explores therapeutic breakthroughs, encompassing liver surgery and transplantation strategies, precision medicine approaches, and the integration of locoregional therapies. Additionally, novel combination therapies that combine traditional treatments like surgery, radiotherapy, and chemotherapy with newer agents offer promising strategies to improve treatment outcomes.
Collaboration and multidisciplinary efforts are highlighted throughout the topic, emphasizing the importance of teamwork between oncologists, surgeons, radiologists, molecular biologists, and other healthcare professionals. Ethical considerations, patient-centered care, and strategies to manage treatment-related toxicities are also explored to ensure holistic patient management.
The overarching objective of this Research Topic is to provide a comprehensive overview of recent advancements in primary liver cancer investigation and treatment, shedding light on the evolving landscape of oncology. By showcasing the integration of cutting-edge research into clinical practice, we expect to provide a forum that contributes to the ongoing effort to improve the lives of individuals affected by primary liver cancer and fosters optimism for future innovations in the field.
We welcome Original Research, Review, Systematic Reviews, Case Reports and Mini-Reviews.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Primary liver cancer represents a significant global health challenge, with its incidence steadily rising and posing substantial morbidity and mortality rates. This research topic in Frontiers in Oncology focuses on the latest advancements in the investigation and treatment of primary liver cancer, addressing hepatocellular carcinoma (HCC) and cholangiocarcinoma to provide insights into cutting-edge approaches to shaping the field and improving patient outcomes.
Contributing researchers delve into multifaceted aspects of primary liver cancer, including molecular pathogenesis, early detection methods, novel imaging techniques, personalized treatment strategies, and innovative therapeutic interventions. With an emphasis on translational research, this Research Topic aims to showcase studies that bridge the gap between laboratory discoveries and clinical applications. Investigations into the intricate molecular mechanisms underlying liver carcinogenesis offer new avenues for targeted therapies and biomarker development, while advancements in non-invasive imaging modalities enhance early diagnosis and disease staging.
The topic also explores therapeutic breakthroughs, encompassing liver surgery and transplantation strategies, precision medicine approaches, and the integration of locoregional therapies. Additionally, novel combination therapies that combine traditional treatments like surgery, radiotherapy, and chemotherapy with newer agents offer promising strategies to improve treatment outcomes.
Collaboration and multidisciplinary efforts are highlighted throughout the topic, emphasizing the importance of teamwork between oncologists, surgeons, radiologists, molecular biologists, and other healthcare professionals. Ethical considerations, patient-centered care, and strategies to manage treatment-related toxicities are also explored to ensure holistic patient management.
The overarching objective of this Research Topic is to provide a comprehensive overview of recent advancements in primary liver cancer investigation and treatment, shedding light on the evolving landscape of oncology. By showcasing the integration of cutting-edge research into clinical practice, we expect to provide a forum that contributes to the ongoing effort to improve the lives of individuals affected by primary liver cancer and fosters optimism for future innovations in the field.
We welcome Original Research, Review, Systematic Reviews, Case Reports and Mini-Reviews.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: combination therapies, translational research, surgery and transplantation, molecular mechanisms, liver carcinogenesis, targeted therapies, biomarker
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
